AI & Machine Learning

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

The new SANY-Pony.ai autonomous truck is production-ready for 2026, promising to slash freight costs, boost profits, and redefine logistics.

After two decades under its visionary founder, Oxford Nanopore taps a commercial scaling expert to lead its next chapter of global growth and market dominance.

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

A Canadian firm's breakthrough promises to produce renewable natural gas at price parity with fossil fuels. Is this the key to unlocking a greener economy?

USA Pickleball's exclusive DUPR deal aims to unify the sport, but a single rating system brings both professional legitimacy and player controversy.

Following a strategic merger, the National Down Syndrome Society appoints six new leaders, signaling a new era of inclusive, research-driven advocacy.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

The Dot Corp's new division signals a major shift in marketing logistics. Why are companies abandoning siloed vendors for a single source of truth?

The G7 has unveiled a new blueprint for the future of work, balancing AI innovation with a major push for inclusive employment. What does it mean?

Shirl Penney's CEO of the Year award signals a major shift. Discover how his model of 'Supported Independence' empowers advisors and reshapes finance.

Beyond the GRAMMYs: How the Lipman brothers leveraged data and strategy to dominate the music industry and redefine the modern record label.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

Seegene expands to France's lucrative diagnostics market, but the real story is its plan to build an automated, data-driven health intelligence network.

As Bitcoin stands firm against a weak altcoin market, the focus shifts to infrastructure. How are staking platforms building trust through security and transparency?

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

Echobit's listing of ORIGYN's AI provenance protocol signals a strategic move into digital asset verification, blending blockchain with AI development.

A new partnership makes launching Global Capability Centers in India faster and more affordable, democratizing access to global talent and innovation.